Log In
BCIQ
Print this Print this
 

neramexane (KRP-209)

  Manage Alerts
Collapse Summary General Information
Company Merz GmbH & Co. KGaA
DescriptionNMDA receptor antagonist
Molecular Target NMDA receptor ; Nicotinic acetylcholine receptor (nAchR)
Mechanism of ActionNMDA receptor antagonist; Nicotinic acetylcholine receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationTinnitus
Indication DetailsTreat subjective tinnitus
Regulatory Designation
PartnerKyorin Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today